Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled flecainide for acute conversion of recent-onset symptomatic paroxysmal atrial fibrillation
2018-000094-76Phase 2Completed
- Sponsor
- InCarda Therapeutics
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of flecainide in Atrial fibrillation (AFib) (2 arms), sponsored by InCarda Therapeutics. Primary endpoint: Feasibility of single and repeat administration. Started Mar 2018; status: completed.
02
Drugs
flecainide
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2018-000094-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000094-76.